"Metabolic Clearance Rate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site.
Descriptor ID |
D008657
|
MeSH Number(s) |
E01.370.225.843 E05.200.843 G03.490 G07.690.595 G07.690.725.513
|
Concept/Terms |
Metabolic Clearance Rate- Metabolic Clearance Rate
- Clearance Rate, Metabolic
- Clearance Rates, Metabolic
- Metabolic Clearance Rates
- Rate, Metabolic Clearance
- Rates, Metabolic Clearance
|
Below are MeSH descriptors whose meaning is more general than "Metabolic Clearance Rate".
Below are MeSH descriptors whose meaning is more specific than "Metabolic Clearance Rate".
This graph shows the total number of publications written about "Metabolic Clearance Rate" by people in this website by year, and whether "Metabolic Clearance Rate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 0 | 1 | 1 |
2001 | 0 | 1 | 1 |
2002 | 0 | 2 | 2 |
2003 | 0 | 2 | 2 |
2005 | 0 | 2 | 2 |
2006 | 0 | 1 | 1 |
2015 | 0 | 1 | 1 |
2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Metabolic Clearance Rate" by people in Profiles.
-
Prediction and Comparison of Fentanyl Infusion Pharmacokinetics in Obese and Nonobese Children. Pediatr Crit Care Med. 2019 12; 20(12):e556-e564.
-
Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. Arthritis Res Ther. 2015 Aug 20; 17:215.
-
Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group. Cancer Chemother Pharmacol. 2014 Oct; 74(4):831-8.
-
Molecular interactions of exogenous chemical agents with collagen--implications for tissue optical clearing. J Biomed Opt. 2006 Jan-Feb; 11(1):014003.
-
PEGylated murine Granulocyte-macrophage colony-stimulating factor: production, purification, and characterization. Protein Expr Purif. 2005 Dec; 44(2):94-103.
-
Mice deficient in corticotropin-releasing factor receptor type 2 exhibit normal ethanol-associated behaviors. Alcohol Clin Exp Res. 2005 Sep; 29(9):1601-9.
-
Radiochemical investigations of 177Lu-DOTA-8-Aoc-BBN[7-14]NH2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells. Nucl Med Biol. 2003 Feb; 30(2):101-9.
-
[99mTc] liposomes for localizing experimental colitis in a rabbit model. Nucl Med Biol. 2003 Feb; 30(2):159-68.
-
Pitfalls of radiation survey after brachytherapy implant removal preceding Tl-201 study. Clin Nucl Med. 2002 Jul; 27(7):494-8.
-
Comparison of pharmacokinetics of lanoteplase and alteplase during acute myocardial infarction. Clin Pharmacokinet. 2002; 41(6):445-52.